According to research published in Sleep Medicine, gabapentin enacarbil significantly improved symptoms in severe primary restless leg syndrome, reports Neurology Advisor.

“Treatment effects compared with placebo were generally numerically greater for GEn 1200 mg than for GEn 600 mg,” the authors wrote. “However, caution should be exercised when interpreting these data for clinical practice purposes, as only GEn 600 mg is currently approved by the FDA for the treatment of moderate-to-severe primary RLS.”